# Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

> **NCT00431561** · PHASE2 · COMPLETED · sponsor: **Isarna Therapeutics GmbH** · enrollment: 141 (actual)

## Conditions studied

- Glioblastoma
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** AP 12009 10 µM
- **DRUG:** AP 12009 80 µM
- **DRUG:** temozolomide or PCV
- **DEVICE:** Drug delivery system for administration of AP 12009
- **PROCEDURE:** Placement of Drug Delivery System

## Key facts

- **NCT ID:** NCT00431561
- **Lead sponsor:** Isarna Therapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2013-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431561, "Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00431561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*